2022 Volume 21 Issue 1 Pages 1-5
A 64-year-old Japanese woman wasreferred to uswith erosionson the lipsand erythematous macules on the trunk and extremities. She had undergone right lateral temporal bone resection,postoperative radiation therapy, and chemotherapy for the right external auditory canal cancer one year before. The eruptionsoccurred 12 daysafter administering nivolumab for recurrence. The eruptions were diagnosed as nivolumab-induced Stevens-Johnson syndrome, an immune-related adverse event with clinical and histopathological features. The lesions were cured after applying steroid pulse therapy, plasma exchange, and intravenous immunoglobulin. To date, six cases of Stevens-Johnson syndrome and one case of toxic epidermal necrosis due to nivolumab have been reported in Japan. To prevent poor prognosis due to nivolumab-associated immune-related adverse events, immediate diagnosis and intensive treatment are required. It would be necessary to accumulate similar case series to establish appropriate management for nivolumab-induced severe immune-related adverse events. Skin Research, 21 : 1-5, 2022
